市场立即捐赠成为会员

购物车 (0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Ottawa Marriott Hotel

2017 年 10 月 17 日 7:00 上午 - 2017 年 10 月 18 日 3:00 下午

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

返回 Agenda

Session 4B: Market Access: Implications for and Piloting the Alignment of HTA and HC Reviews, and Comprehensive Economic and Trade Agreement (CETA)

Session Chair(s)

Keith McIntosh

Executive Director, Scientific & Regulatory Affairs, Innovative Medicines Canada, Canada

This session will focus on regulatory policies realted to market access. Attendees will learn about the approaches for HTA and regulatory approvals in Canada, and hear directly from Health Canada and CADTH about the work underway to streamline and coordinate these processes. The session will also examine the implication of CETA on pharmaceutical protection, including what benefits CETA may bring to Canadian consumers, patients and the economy.

Speaker(s)

Kelly Lehman

Associate Director, Health Canada, Canada

Piloting the Alignment of HTA and HC Reviews

Alexandra Chambers

Alexandra Chambers

Director, CADTH, Canada

Co-Presenter

Cheryl Cheung

Cheryl Cheung

Intellectual Property Counsel, Pharmascience, Canada

The Implication of CETA on Pharmaceutical Patent Protection